Published in Malaria Weekly, May 18th, 2009
"Our assay uses species-specific forward primers in combination with a conserved reverse primer and largely overcomes primer competition for the minor species DNA. With a blind panel of clinical samples, we successfully identified the species in 13/16 mixed infections. This assay was further validated with 91 blood samples and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Malaria Weekly
Source: Malaria Weekly (2009-05-18)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.